--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About FOLD20260220C14
Biological Technology
Amicus Therapeutics, Inc., was incorporated under the laws of the State of Delaware on February 4, 2002. The company is a global, patient-centric biotechnology company focused on discovering, developing and delivering new drugs for rare diseases. The company seeks to provide the highest quality therapies that have the potential to phase out current therapies, provide significant benefits to patients, and become first class or first class. The two therapies the company has marketed are Galafold, the first oral monotherapy for Fabry disease patients with compliant gene variants, and Pombiliti + Opfolda, a novel therapy designed to increase active enzyme uptake in key disease-related tissues in adults with late-onset Pompe disease.
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
